Alivus Life Sciences Q1 FY27 PAT up 32% on 6% sales

Key takeaway from the Q1 FY27 print

Alivus Life Sciences reported a strong operating quarter in Q1 FY27, marked by faster profit growth than revenue growth. Standalone profit after tax (PAT) rose 31.8% year-on-year (YoY) to ₹160.08 crore, while revenue from operations increased 6.4% YoY to ₹640.41 crore. The company attributed the performance to a highly favourable product mix and a sharp improvement in operating efficiency. EBITDA margins expanded to 36.6%, which the company linked to operating leverage and rationalised input costs. The results were approved at a Board meeting held on July 30, 2026.

Revenue growth led by non-GPL segment

The company highlighted strong traction in its non-GPL business, which grew 26.5% YoY in the quarter. This segment performance was positioned as a key driver behind the overall revenue increase, even as the broader business continues to balance exposure to the Glenmark Pharmaceuticals (GPL) side. The article note described Alivus as entering the Q1 FY27 window with “structural margin expansion” alongside “inherent volatility” in the GPL business. While overall top-line growth was in mid-single digits, the mix shift towards non-GPL products and geographies supported better profitability. The reported revenue from operations for Q1 FY27 was ₹640.41 crore, compared with ₹601.80 crore in the year-ago quarter.

Profit rises faster than sales as margins expand

PAT for Q1 FY27 came in at ₹160.08 crore, up from ₹121.54 crore in Q1 FY26. EBITDA rose 29.1% YoY to ₹234.10 crore, supported by the margin expansion to 36.6%. The company quantified margin expansion at 650 basis points YoY. Management commentary in the note pointed to operating leverage benefits and lower input costs after rationalisation. The quarter’s performance was also described as being helped by a favourable product mix.

Cash flows and balance sheet position

Alivus reported free cash flow generation of ₹90.10 crore during Q1 FY27. The company stated it remains net debt-free. Cash and cash equivalents (including short-term investments) stood at ₹880.20 crore at the end of the quarter, up from ₹782.40 crore at the end of FY26. The combination of high operating margins and positive free cash flow was presented as a key support for balance sheet strength.

Board meeting, trading window, and earnings call schedule

The Board of Directors met on July 30, 2026, to approve the Q1 FY27 financial results. Earlier, on July 23, 2026, the company announced the closure of its trading window and scheduled the Q1 earnings conference call. The earnings call is scheduled for July 31, 2026, from 8:30 AM to 9:30 AM IST. The trading window for designated persons was stated to be closed from July 1, 2026, to August 1, 2026.

Solapur greenfield facility update

The company stated it remains on track to make Phase 1 of its Solapur greenfield facility operational in Q2 FY27. This operational milestone is being tracked by the market alongside profitability and margin sustainability targets. Separate market commentary in the note also flagged attention on the company’s goal of sustaining EBITDA margins above 30%. The facility ramp-up timeline, as provided, is one of the near-term operational updates investors are likely to watch during the earnings call.

Quick market datapoints mentioned in the note

The article included multiple market snapshots and quick details, indicating different points-in-time pricing and market capitalisation references. One snapshot cited a CMP of ₹1,101.2 and market cap of ₹13,516.07 crore. Another section cited Alivus Life Sciences shares trading at ₹1,179 with a market capitalisation of ₹14,232 crore, and also referenced a price-to-earnings multiple of 25.2. A separate stock data block in the note mentioned a current price of ₹1,048 and market cap of ₹12,850.31 crore, along with other ratios.

Key numbers at a glance

Market impact

The note said the strong Q1 earnings are likely to boost investor confidence and support a positive re-rating of the stock, while remaining anchored to execution in core segments. From a fundamentals perspective, the most direct market-relevant change was the sharp margin expansion to 36.6%, alongside a 31.8% YoY increase in PAT. Free cash flow of ₹90.10 crore and a net debt-free status add to the financial flexibility narrative, especially when paired with ₹880.20 crore in cash reserves. The scheduled earnings call on July 31, 2026 sets a near-term event for investors to seek clarity on business mix, non-GPL momentum, and the Solapur commissioning timeline.

Analysis: why the quarter matters

The quarter highlights how product mix and operating leverage can meaningfully change earnings even when revenue growth is modest. With revenue up 6.4% YoY and EBITDA up 29.1% YoY, the operating margin shift was the primary driver of profit growth. The 26.5% YoY growth cited for the non-GPL business is an important data point because it suggests that growth is not solely dependent on the GPL-linked stream. At the same time, the note explicitly referenced volatility in the GPL business, which frames why investors may focus on segment commentary and sustainability of the margin level. Updates on Phase 1 of the Solapur greenfield facility becoming operational in Q2 FY27 could also influence how the market assesses future capacity and execution.

Conclusion

Alivus Life Sciences delivered Q1 FY27 standalone revenue of ₹640.41 crore and PAT of ₹160.08 crore, supported by a 36.6% EBITDA margin and positive free cash flow. The Board approved the results on July 30, 2026, and the company is scheduled to host its earnings call on July 31, 2026. Investors are also tracking the company’s stated plan to operationalise Phase 1 of the Solapur greenfield facility in Q2 FY27. Further details on segment performance, margin drivers, and execution priorities are expected during the scheduled call.